Consistent with this model, pharmacologic JAK inhibition effectively disrupted the adaptive response and enhanced the anti-tumor efficacy of arginine depletion, validating JAK-STAT as a strategic node for metabolic–immunologic combination therapy. Here, SOAT1 is linked to neoplasm.